E-resources
-
Ramalingam, Suresh S; Vansteenkiste, Johan; Planchard, David; Cho, Byoung Chul; Gray, Jhanelle E; Ohe, Yuichiro; Zhou, Caicun; Reungwetwattana, Thanyanan; Cheng, Ying; Chewaskulyong, Busyamas; Shah, Riyaz; Cobo, Manuel; Lee, Ki Hyeong; Cheema, Parneet; Tiseo, Marcello; John, Thomas; Lin, Meng-Chih; Imamura, Fumio; Kurata, Takayasu; Todd, Alexander; Hodge, Rachel; Saggese, Matilde; Rukazenkov, Yuri; Soria, Jean-Charles
New England journal of medicine/The New England journal of medicine, 01/2020, Volume: 382, Issue: 1Journal Article
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall survival was 38.6 months with osimertinib and 31.8 months with erlotinib or gefitinib. This 20% lower risk of death was noted despite the crossover of patients from standard therapy to osimertinib during subsequent therapy.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.